Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia

Douglas E. Gladstone, Lode Swinnen, Yvette Kasamon, Amanda Blackford, Christopher D. Gocke, Constance A. Griffin, Javier Bolanos Meade, Richard J. Jones

Research output: Contribution to journalArticle


Among prognostic factors for chronic lymphocytic leukemia (CLL), immunoglobulin heavy chain variable region (IGHV) mutation status and DNA analysis appear to be the most important. However, there is limited clinical outcome information for patients with the favorable-risk del(13q) and poor-risk unmutated IGHV. We retrospectively screened all patients with CLL at our institution between 2004 and June 2010 for del(13q) who also had an IGHV analysis. Unmutated IGHV was found in 38/79 patients; age, Rai stage, prior therapy, and time to evaluation were similar to those for patients with mutated IGHV. Unmutated patients were nearly four times more likely to harbor additional chromosomal aberrations compared to mutated patients (p<0.001). During a median follow-up of 4.5 years, unmutated patients were more likely to demonstrate Rai stage progression (69% vs. 31%, log-rank p<0.001) and to receive treatment (5-year cumulative probability of treatment: 65% vs. 32%, p<0.001). Patients with unmutated CLL also had a shorter overall survival (5-year survival probability: 72% vs. 100%, p<0.001). When limiting analysis to the 47 patients with del(13q) as a sole chromosomal abnormality, the 13 (28%) unmutated patients were more likely to demonstrate Rai progression (p<0.001), to receive treatment (p=0.02), and to have a shorter overall survival (p=0.13) than the 34 mutated patients. These data suggest that del(13q) conveys an indolent course only in patients with IGHV-mutated CLL.

Original languageEnglish (US)
Pages (from-to)1873-1881
Number of pages9
JournalLeukemia and Lymphoma
Issue number10
StatePublished - Oct 1 2011



  • CLL
  • IGHV
  • clinical outcomes
  • del(13q)
  • overall survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this